Dr Reddy's Laboratories Ltd has received approval from the US Food and Drug Administration to market its anti-infective ciprofloxacin extended-release tablets.

Dr Reddy's Laboratories Ltd has received approval from the US Food and Drug Administration to market its anti-infective ciprofloxacin extended-release tablets.The drug maker also received approval to market rivastigmine tartrate capsules, a generic variant of Novartis' Exelon capsules, indicated in the treatment of mild dementia associated with Alzheimer's disease and Parkinson's disease.

Dr Reddy’s core businesses of Active Pharmaceutical Ingredients (API) and Branded Formulations are well established with an impressive track record of growth and profitability. Our Generics business started operations in 2001 and focuses primarily on the North America and EU markets. The company has built a robust pipeline of generic products, which will help us drive growth in the medium and long term. In addition, the company is investing in creating businesses of the future – the innovation led businesses – of Specialty and Drug Discovery. The company’s revenues for fiscal 2007 are U.S. $1.51 billion.